Protease inhibitor (pharmacology)

Protease inhibitors (PIs) are medications that act by interfering with enzymes that cleave proteins. Some of the most well known are antiviral drugs widely used to treat HIV/AIDS and hepatitis C. These protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles.

For natural protease inhibitors, see Protease inhibitor (biology). For inhibitors of cellular proteases, see Proteasome inhibitor and Matrix metalloproteinase inhibitor.

Protease inhibitors that have been developed and are currently used in clinical practice include:

Given the specificity of the target of these drugs there is the risk, like with antibiotics, of the development of drug-resistant mutated viruses. To reduce this risk, it is common to use several different drugs together that are each aimed at different targets.

Antiretrovirals

Protease inhibitors were the second class of antiretroviral drugs developed. The first members of this class, saquinavir, ritonavir, and indinavir, were approved in late 1995–1996. Within 2 years, annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000[3] Prior to this the annual death rate had been increasing by approximately 20% each year.

The number of people in the U.S. dying of HIV fell by 60% in the 2 years following the introduction of the first HIV protease inhibitors
NameTrade nameCompanyPatentFDA approval dateNotes
SaquinavirInvirase, FortovaseHoffmann–La RocheU.S. Patent 5,196,438December 6, 1995The first protease inhibitor approved by the U.S. Food and Drug Administration (FDA).
RitonavirNorvirAbbVieU.S. Patent 5,541,206March 1, 1996AbbVie was part of Abbott Laboratories when patent was granted. As well as being a protease inhibitor in its own right, ritonavir inhibits the breakdown of other protease inhibitors. This property makes it very useful in drug combinations.[4]
IndinavirCrixivanMerck & Co.U.S. Patent 5,413,999March 13, 1996—
NelfinavirViraceptHoffmann–La RocheU.S. Patent 5,484,926March 14, 1997—
AmprenavirAgeneraseGlaxoSmithKlineU.S. Patent 5,585,397April 15, 1999The sixteenth FDA-approved antiretroviral. It was the first protease inhibitor approved for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in 8 very large gel capsules. Production was discontinued by the manufacturer December 31, 2004, as it has been superseded by fosamprenavir.
LopinavirKaletraAbbVieU.S. Patent 5,914,332September 15, 2000Is only marketed as a fixed-dose combination with ritonavir (see lopinavir/ritonavir). AbbVie was part of Abbott Laboratories when patent was granted.
AtazanavirReyatazBristol-Myers SquibbU.S. Patent 5,849,911June 20, 2003Atazanavir was the first PI approved for once-daily dosing. It appears to be less likely to cause lipodystrophy and elevated cholesterol as side effects. It may also not be cross-resistant with other PIs.
FosamprenavirLexiva, TelzirGlaxoSmithKline—October 20, 2003A prodrug of amprenavir. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow release version of amprenavir and thus reduces the number of pills required versus standard amprenavir.
TipranavirAptivusBoehringer Ingelheim—June 22, 2005Also known as tipranavir disodium.
DarunavirPrezistaJanssen TherapeuticsU.S. Patent 6,248,775June 23, 2006As of 2016, darunavir is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents.[5] Several ongoing phase III trials are showing a high efficiency for the darunavir/ritonavir combination being superior to the lopinavir/ritonavir combination for first-line therapy.[6] Darunavir is the first drug in a long time that didn't come with a price increase. It leapfrogged two other approved drugs of its type, and is matching the price of a third.[7][8][9]

Other activities

Non-antiretroviral antiviral activity

A drug combination targeting SARS-CoV-2 from Pfizer, Paxlovid, was approved on December 22, 2021.[10] It is a combination of nirmatrelvir, a protease inhibitor targeted to SARS-CoV-2's 3C-like protease, and ritonavir to inhibit nirmatrelvir's metabolism

Protease inhibitors also are used to treat Hepatitis C.

Antiprotozoal activity

Researchers are investigating the use of protease inhibitors developed for HIV treatment as anti-protozoals for use against malaria and gastrointestinal protozoal infections:

  • A combination of ritonavir and lopinavir was found to have some effectiveness against Giardia infection.[11]
  • The drugs saquinavir, ritonavir, and lopinavir have been found to have anti-malarial properties.[12]
  • A cysteine protease inhibitor drug was found to cure Chagas disease in mice.[13]

Anticancer activity

Researchers are investigating whether protease inhibitors could possibly be used to treat cancer. For example, nelfinavir and atazanavir are able to kill tumor cells in culture (in a Petri dish).[14][15] This effect has not yet been examined in humans; but studies in laboratory mice have shown that nelfinavir is able to suppress the growth of tumors in these animals, which represents a promising lead towards testing this drug in humans as well.[15]

Inhibitors of the proteasome, such as bortezomib are now front-line drugs for the treatment of multiple myeloma.

Tanomastat is one of the matrix metalloproteinase inhibitors that can be used to treat cancer. Batimastat was also well known from Lednicer book.

Side effects

Protease inhibitors can cause a syndrome of lipodystrophy, hyperlipidemia, diabetes mellitus type 2, and kidney stones.[16] This lipodystrophy is colloquially known as "Crix belly", after indinavir (Crixivan).[17]

See also

References
  1. "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. Retrieved 5 November 2016.
  2. Ahmad B, Batool M, Ain QU, Kim MS, Choi S (August 2021). "Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations". International Journal of Molecular Sciences. 22 (17): 9124. doi:10.3390/ijms22179124. PMC 8430524. PMID 34502033.
  3. "HIV Surveillance --- United States, 1981--2008". Retrieved 8 November 2013.
  4. British National Formulary 69 (69 ed.). Pharmaceutical Pr. March 31, 2015. p. 426. ISBN 9780857111562.
  5. "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents" (PDF). Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents—A Working Group of the Office of AIDS Research Advisory Council (OARAC). July 14, 2016. Retrieved 5 November 2016.
  6. Madruga JV, Berger D, McMurchie M, et al. (Jul 2007). "Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial". Lancet. 370 (9581): 49–58. doi:10.1016/S0140-6736(07)61049-6. PMID 17617272. S2CID 26084893.
  7. Liz Highleyman, Patient Advocates Commend Pricing of New PI Darunavir, http://www.hivandhepatitis.com/recent/2006/ad1/063006_a.html
  8. Darunavir - first molecule to treat drug-resistant HIV
  9. Borman S (2006). "Retaining Efficacy Against Evasive HIV: Darunavir analog to AIDS-virus shapeshifters: Resistance may be futile". Chemical & Engineering News. 84 (34): 9. doi:10.1021/cen-v084n034.p009.
  10. "FDA authorizes 1st antiviral pill for COVID --- United States, 2021". NPR. Retrieved 22 December 2021.
  11. Dunn LA, Andrews KT, McCarthy JS, et al. (2007). "The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis". Int. J. Antimicrob. Agents. 29 (1): 98–102. doi:10.1016/j.ijantimicag.2006.08.026. PMID 17137752.
  12. Andrews KT, Fairlie DP, Madala PK, et al. (2006). "Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria". Antimicrob. Agents Chemother. 50 (2): 639–48. doi:10.1128/AAC.50.2.639-648.2006. PMC 1366900. PMID 16436721.
  13. Doyle PS, Zhou YM, Engel JC, McKerrow JH (2007). "A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection". Antimicrobial Agents and Chemotherapy. 51 (11): 3932–9. doi:10.1128/AAC.00436-07. PMC 2151429. PMID 17698625.
  14. J.J. Gills, et al. (2007). "Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo". Clinical Cancer Research. 13 (17): 5183–94. doi:10.1158/1078-0432.CCR-07-0161. PMID 17785575.
  15. Pyrko, P.; Kardosh, A; Wang, W; Xiong, W; Schönthal, AH; Chen, TC (2007). "HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress". Cancer Research. 67 (22): 10920–8. doi:10.1158/0008-5472.CAN-07-0796. PMID 18006837.
  16. Fantry, LE (2003). "Protease inhibitor-associated diabetes mellitus: A potential cause of morbidity and mortality". Journal of Acquired Immune Deficiency Syndromes. 32 (3): 243–4. doi:10.1097/00126334-200303010-00001. PMID 12626882.
  17. Capaldini, L. (1997). "Protease inhibitors' metabolic side effects: cholesterol, triglycerides, blood sugar, and "Crix belly"". AIDS Treatment News (277): 1–4. PMID 11364559.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.